![]() |
![]() | ![]() |
We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
![]()
CuraGen is a biotechnology company pioneering the systematic application of genomics to accelerate the discovery & development of therapeutic and agricultural products. Of all of the biotechnology sub-disciplines in terms of return on investment, genomics is purported to have one, if not the highest potential. In layman's language, CuraGen thinks they can speed up the tedious, therefore expensive, processes of finding genes which code for proteins involved in disease processes. They claim they have developed automated, "high-throughput" means of also discovering chemicals which can interact with these proteins, thereby altering a disease process. They propose to computerize the whole, complicated database, and make money by charging subscription fees, by engaging in research collaborations, and by retaining product rights for revenues and royalties. | ||||||||||||||
|
Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
© 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |